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Introduction
Diabetes mellitus is a disorder recognized with increase of blood 
sugar level. Impaired insulin release or failure to respond to insulin 
or both is the cause of this disorder. Chronic hyperglycemia leads to 
the dysfunction of several organs especially eye, kidney, heart and 
vessels [1]. Peripheral neuropathy is one of the common complications 
of diabetes which in turn increases the risk of other diabetes 
complications such as foot ulcers and amputation [1]. Almost more 
than half of diabetic patients suffer from different forms of neuropathy 
after passing 1-2 decades of their disease [2,3]. In animal models of 
streptozotocin-induced diabetes, this time has decreased to at least 
two weeks [4]. Peripheral diabetic neuropathy is the result of several 
factors [5-7] and its probable mechanisms include glycosylation of 
neural proteins, microangiopathy, neuronal antibodies and ischemia 
resulted from basement membrane thickening of the vasa nervorum. 
Abnormalities of polyol pathway and defects of protein kinase C 
metabolism which cause nerve demyelinating have also been described 
in diabetic peripheral neuropathy [6]. Based on these mechanisms of 
injury, various prevention and treatment strategies have been already 
suggested and are under investigation. For instance, the effects of several 
antioxidants such as vitamin E [8], melatonin [9] and date extract [10], 
fatty acid contained diets like Omega 3 [11], aldosereductase inhibitors 
[12] and also statins compounds such as atorvastatin [13] have been 
investigated, but none of them have already been approved by FDA. At 
present, there is no definite treatment for this complication.
Cerebrolysin is a neuropeptide anti-inflammatory mixture isolated 
from pig brain tissue [14]. It is a neurotrophic peptidregic mixture 
resulted from enzymatic breakdown of free- lipid porcine brain 
proteins. It contained 25% low molecular weight peptides (<10 KDA) 
and 75% free amino acids depending on free nitrogen content [15]. 
Cerebrolysin contains relatively high concentrations of magnesium, 
potassium, phosphorus, selenium [16] and also other elements [17,18].
Cerebrolysin was first used in 1973 [19] as a hydrolysate in patients 
with cerebral arteriosclerosis. It has been suggested for several types of 
nerve degeneration disorders [20-22], organic mental disorders [21], 
Multiple sclerosis [22], anti-aging [23] and ischemic encephalopathy 
[24]. This medicine has also been applied in the treatment of pediatrics 
cerebral paralysis, elderly patients and some other conditions [25]. It 
has been recognized in a comparative study that antioxidant properties 
of cerebrolysin is approximately 300 times less than that of trolox 
(vitamin E) [26].
In regard to the positive effects of cerebrolysin on neurotic 
disorders reported in previous studies, the present study was designed 
to investigate cerebrolysin as an effective mixture in the process of 
ischemia and improvement of diabetic neuropathy.
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Abstract
Objective: Diabetes mellitus with 10% prevalence in human population leads to disorders of peripheral nervous 
system in many affected patients. It causes various polyneuropathies in which nerve conductionvelocity decreases. 
The aim of this study was to investigate the effect of cerebrolysinon the treatment of neural injuries resulted from 
hyperglycemia.
Method: Diabetes was induced in male rats weighing 250 ± 25 gr by intraperitoneal injection of 65 mg/kg 
streptozocin (STZ). Six weeks after STZ injection and appearance of neuropathy in diabetic rats, animals were 
divided into four groups: experimental, vehicle, diabetic and control. The experimental and vehicle groups received 
respectively single dose of 5 mg/kg day-1 cerebrolysinand saline intraperitoneally for two weeks. At the end, in 
order to find the efficacy of cerebrolysin, all groups underwent behavioral and electrophysiological tests as well as 
histological investigation.
Results: Metabolic parameters in different groups showed inefficacy of cerebrolysin in the treatment of metabolic 
disorders of diabetes. However, electrophysiological investigations showed efficacy of cerebrolysin in the treatment 
of diabetic neuropathy in rats. Moreover, investigation on morphologic structure of sciatic nerve was evident of the 
return of axon degenerative changes and myelin splitting in nerve fibers in cerebrolysin-received group. The results 
of behavioral studies showed increase in recovery in cerebrolysin group.
Conclusion: According to the results, treatment of diabetic neuropathy with daily injection of 5 mg/kg cerebrolysin 
for two weeks improves rats’ condition.
Citation: Zangiabadi N, Mohtashami H, Shabani M, Jafari M (2014) Neuroprotective Effect of Cerebrolysin on Diabetic Neuropathy: A Study on Male 
Rats. J Diabetes Metab 5: 357 doi:10.4172/2155-6156.1000357
Page 2 of 7
Volume 5 • Issue 4 • 1000355J Diabetes MetabISSN: 2155-6156 JDM, an open access journal
Material and Methods
Animals 
In the present study, male NMRI rats weighing 250 ± 25 gr kept in 
the animal house of Kerman Neuroscience Research Center were used. 
Animals were kept at 25 ± 1°C, 12/12 h light/darkcycle and free access 
to the same food and water. The study protocol was approved by the 
animal ethics committee of this institution (Code:EC/KNRC/88-15).
Diabetes induction
Rats were divided into four groups: First group consisted of control 
animals. The second, third and fourth groups consisted of diabetic 
animals (at least 8 rats in every group).
In order to induce diabetes, streptozotocin purchased from Sigma 
Company(65 mg/kg in 100 mmol/L sodium citrate buffer, pH4.5) was 
intraperitoneally injected into at least 24 rats [27]. One week after 
STZ injection, animals with fasting blood sugar higher than 200 mg/
dl were selected for experiments. Six weeks after the injection of STZ 
and appearance of neuropathy in diabetic animals [27,28], First group 
(Control): received nothing, second group (Diabetic): received nothing, 
third group (Vehicle): received 5 ml/kg day-1 saline intraperitoneally 
for 2 weeks and fourth  group (Experimental): received 5 ml/kgday-
1cerebrolysinintraperitoneally for two weeks. This dose of cerebrolysin 
has been identified as neuroprotective inducing dose in nerve injuries 
[29,30].
Tail flick test
Tail flick is one of the standard tests for measuring the rate of 
analgesia. In this test, thermal light with the intensity of 5 was directed 
on the distal part of the animal’s tail by Tail flick instrument (made 
by Spanish Lsi LETICA, model LE7406) and tail flick latency was 
measured. In order to prevent tissue damage, light was directed for a 
maximum time of 10 seconds. For each animal, tail flick latency was 
measured three times with 5 minutes intervals and mean of them was 
reported as tail flick latency [31].
Open field test
Open field test was used in order to survey the effect of diabetic 
neuropathy on exploratory behavior of diabetic rats and the probable 
protective effect of Cerebrolysin. Exploratory behavior was investigated 
by a video tracking system (TSE) in a 45*45*45cm box. At the end of 6th 
week after diabetes induction, animals were placed in the center of the 
arena and their exploratory behavior including horizontal, central and 
peripheral paved distances were measured for 5 minutes. The duration 
of staying in the center and peripheral parts as well as the velocity of 
movement were investigated [32].
Electrophysiological evaluation
Six weeks after the initiation of hyperglycemia, animals were 
anesthetized with intraperitoneal injection of 50/20 mg/kg ketamine+ 
xylazine solution. The environment temperature was kept at 25 ± 1°C 
during all phases of experiments. After shaving back of animal’s leg, 
a small incision was made in the right sciatic notch and ankle. Then, 
using bi-polar electrodes, the proximal part of sciatic nerve at the 
sciatic notch and the distal part at the ankle were stimulated and motor 
neuron conduct velocity (MNCV) of sciatic-tibial motor nerve was 
recorded (powerlab/ML856;AD Instruments, Sydney, NSW, Australia). 
Immediately after stimulation, action potential of the first interosseous 
muscle of back paw was recorded by mono-polar electrodes. The 
obtained records are biphasic responses with one primary m wave 
appeared due to the stimulation of motor fibers. Motor nerve conduct 
velocity (m/s) is calculated through dividing the distance between two 
stimulated points (mm) by the time difference of two stimulations 
[10,33].
Histopathological evaluation
After the experiments related to NCV, animals were anesthetized 
with 400 mg/kg chloral hydrate and following cardiac perfusion by 
using saline and bouin’s fixative [34]. Then a section of sciatic nerve (1 
cm) was removed and kept in bouin’s fixative. Forty eight hours after 
remaining in fixative, it underwent tissue processing phases and was 
embedded in paraffin. Then 4 µm sections were prepared and stained 
with hematoxylin-eosin for surveying by light microscope(Motic 
Images China e-kup Co., Ltd)(x400) [35].
In this evaluation, axons of nerves in sciatic transversesection were 
investigated in regard to edema andaxoplasm state (demyelination and 
remyelination) [36].
Statistical analysis
Parametric paired t-test was used for comparison of coupled 
primary and secondary variables and in order to compare quantitative 
variables among groups ANOVA was applied. Tukey test was used in 
the case of significant difference and in the case of rejection of null 
hypothesis, non-parametric Kruskal Wallis was applied.
Results
Metabolic parameters
In all diabetic groups, mean plasma concentration in the 8th week 
was 280% more than that in the control group. All diabetic rats showed 
high blood sugar and weight gain disorder in the 8th week after STZ 
injection. As it has been presented in Table1, weight of diabetic animals 
compared to the non-diabetic control group had significantly decreased 
in the 8th week (Table 1).
The effect of cerebrolysin on tail flick test
Diabetic neuropathy caused significant increase in reaction to pain 
and tail flick latency time in diabetic, vehicle and cerebrolysin groups 
compared to the control group, but diabetic and vehicle groups showed 
no significant difference with cerebrolysin-received group in this regard 
(Figure 1).
Animal group
Body weight (g) Blood glucose (mg dL1)
Before STZ injection End experiment Before STZ injection End experiment
Control (8) 243/25 ± 30/36 * 279/62 ± 28/91 147/37 ± 13/05 161/12 ± 28/36
Sham (8) 255/42 ± 17/01 230/85 ± 22/95 454/28  ± 73/61 463/71 ± 62/27 × × ×× 
Vehicle (8) 235/80 ± 23/74 204/00 ± 26/19 503/50 ± 39/28 520/50 ± 53/29 × × × ×
Cerebrolysin (8) 255/22 ± 24/68 208/33 ± 20/40 523/83 ± 34/60 533/16 ± 66.51 × × ×× 
Data are the Mean ± SEM (n = 8). × × ××   p<0.0001, compared with the control group
Table 1: Body weight and blood glucose levels of all groups.
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The results of open field test
The analysis of data related to “total distance moved”, “mobility”, 
“immobility” and “velocity” in open field test showed no significant 
difference among studied groups (Figure 2).
Nerve Conduct Velocity
In regard to mean NCV, vehicle and diabetic groups showed 
significant difference with the control group (p=0.000 and p=0.000 
respectively), and also they had significant difference with cerebrolysin-
16
14
12
10
8
6
4
2
0
cerebrolysin           control                 sham                 vehicle
Group
Ta
il 
fli
ck
 (s
)
* **
***
Figure 1: Effect of cerebrolysin (5 mg kg day-1, ip, for 2 weeks) on the pain threshold values in streptozotocin-injected diabetic rats subjected to tail flick. *P<0.05, 
**P<0.01 and ***P<0.001 as compared to control group. There are no significance effects between cerebrolysin-treated and diabetic groups. Values are expressed 
as mean ± SEM. (n=8 rats in each group).
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Figure 2: Effect of cerebrolysin on explorative behavior of rats in open field test. (A) Total distance moved , (B) movement (C) not movement and (D) velocity. Data 
are the Mean ± SEM. (n=8 rats in each group).
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received group (p=0.012 and p=0.024 respectively). While There are no 
significance effects between cerebrolysin-treated and control groups 
(p=0.107). This finding shows significant efficacy of cerebrolysin in 
improving nerve function in the cerebrolysin-received group compared 
to vehicle and diabetic groups (Figure 3).
The effect of cerebrolysin on morphological alterations of 
nerve myelin
Microscopic investigations showed normal structure and 
morphology of myelin in the control group, but in the diabetic and 
vehicle groups, edema and myelin sheath splitting were observed. 
Increase in the number of fibers with abnormal myelin was observed 
in the diabetic and vehicle groups. Treatment with cerebrolysin could 
prevent abnormal cases in a wide extent. Data related to the myelin 
and axon diameters of nerve fibers in the vehicle and diabetic groups 
showed significant decrease in comparison to the control group. 
Cerebrolysin administration caused significant improvement in myelin 
and axon diameter reduction among diabetic rats in two weeks (Table 
2 and Figure 4).
Discussion
In several in vivo and in vitro studies, neuroprotective and 
neurotrophic effects of cerebrolysin have been reported. Cerebrolysin 
has caused improvement in cell oxidative stress during cerebral 
ischemia in animals.  
Considering the identified properties of cerebrolysin as a 
neuropeptide anti-inflammatory mixture [14] and also previous related 
studies, the probable mechanism of cerebrolysin effect on diabetic 
neuropathy can be explained as follow.
Since ischemia is associated with decrease of blood flow followed 
by oxygen and food shortage and consequently stopping of energy 
production in tissue vessels, it has a significant role in producing and 
extension of pathologic changes in various neuropathies including 
peripheral neuropathies especially in sciatic nerve. These pathologic 
alterations in nerves are related to the degeneration of fibers and edema. 
In ischemia phase, blood flow stopping and oxygen shortage result in 
anaerobic metabolism, energy loss, ATP decrease and accumulation of 
hypoxanthine in ischemic cells. Lack of energy affects ATPase ion pump 
of cell membrane and causes sodium, calcium and water accumulation 
and consequently cell edema [37].
Gusev et al. [38], treated 30 patients with severe ischemic strokes by 
administering 10, 20 and 30 mg/day cerebrolysin for 10 days and have 
reported improvement in patients with moderate disease in comparison 
to their control group. Indeed, cerebrolysin improves motor activities 
and EEG signals in rats with moderate ischemia in anterior portion of 
brain. Also cerebrolysin has high neurotrophic property due to having 
very useful compounds such as 25% low density proteins (KDA<10), 
75% free amino acids [15], high concentrations of magnesium, 
potassium, phosphor and selenium [16] and also some other elements 
[18,38]. This medicine, through providing the nerve cell with these 
elements, helps both cell metabolism process and remyelination.
Neuroplasticity involves the activation of existing but silent 
connections, synaptogenesis, dendritic arborization and new nervous 
cell production [17]. Neuroplasticity can be enhanced by administration 
of neurotrophic factors [39]. Due to its unique composition consisting 
of active fragments of neurotrophic factors, Cerebrolysin is able to 
confer neuroprotection and to stimulate neuroplasticity, thereby 
enhancing the neurorecovery process [40,41].
The other mechanism for explaining cerebrolysin effect is its 
antioxidant property [26,42]. In the process of diabetic neuropathy, 
nerve cells and vessels’ membranes are not dependent to insulin for 
transferring glucose and in diabetes disorder great amount of glucose 
enter cells. In nerve cells, glucose changes to sorbitol by aldose reductase 
enzyme and sorbitol accumulation increases free radicals such as 
hydroxyl-super oxide and hydrogen peroxide and eventually causes 
cell damage. Based on this mechanism of injury, different prevention 
and treatment approaches are under investigation [43,44]. As it was 
mentioned in the introduction, anti-oxidant property of cerebrolysin 
is 300 times less compared to vitamin E [26]. Therefore, it seems that 
cerebrolysin with its minor anti-oxidant property could remove free 
radicals to some extent and caused improvement of diabetic neuropathy.
Diabetic neuropathy in its early stages is associated with increase 
of nerve fiber activity and disorder of normal sensitivity of peripheral 
nervous system to injuries and painful stimulators resulted from 
diabetic hyperalgesia [33,45]. However, after passing early stage the 
sensitivity of peripheral nerves decreases and caused various range of 
analgesia.
According to the obtained results in the present study, cerebrolysin 
(5 ml/kg/day, ip) can exert positive effects within two weeks in the 
treatment and decreasing the physiological symptoms of diabetic 
neuropathy in male rats. In the present study, response time to thermal 
pain in tail flick test showed significant increase in the diabetic group 
in comparison to the control group that is due to diabetic analgesia. 
Cerebrolysin could not significantly reduce this analgesia [46]. 
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Figure 3: Effect of cerebrolysin on motor nerve conductive velocity (MNCV) 
in rats. ‎****‎P<0.0001  as compared to control group; #P<0.05  as compared 
to cerebrolysin-treated group. Data are the Mean ± SEM. (n=8 rats in each 
group).
Groups MSD (μm) AD (μm) MMFD (μm) N
Control 7.96 ± 0.98 6.53 ± 0.932 14.50 ± 0.778 6
Cerebrolysin 6.74 ± 0.735 6.63 ± 0.742 13.38 ± 0.918 6
Sham 4.59 ± 0.453 5.00 ± 0.446 9.59 ± 0.657 6
Vehicle 4.71 ± 0.247 4.98 ± 0.485 9.70 ± 0.296 6
N: Number of animals; MMFD: Mean-Myelinated Fiber  Diameter; AD: Axon 
Diameter; MSD: Myelin Sheath Diameter. Data are presented as Mean ± SEM.
Table 2: The effect of DFE on histomorphometric parameters of rat sciatic nerve.
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In open field test, it was seen that although cerebrolysin cannot 
exert significant improvement in behavioral variables in comparison 
to diabetic controls, in some extent it can improve (even though non-
significantly) diabetic neuropathy. 
Mean NCV in the diabetic group showed 50% reduction in 
comparison to the control group that shows high neuropathy 
percentage in diabetic rats. Indeed, it was observed that intraperitoneal 
injection of cerebrolysin can significantly cause improvement of NCV 
in neuropathy-induced male rats.  
The presence of abnormal fibers in sciatic nerve that showed 
degenerative changes of axon and myelin splitting was one of the 
other symptoms of STZ-induced diabetic rats. In fact, one of the 
main reasons of nerve activity reduction in the process of diabetic 
neuropathy disorder, is morphological changes occurred due to nerve 
metabolic disturbances. In the present study, we observed the efficacy 
of cerebrolysin in improving morphological injuries of sciatic nerve 
myelin in rats with diabetic neuropathy. Morphological observations 
showed remyelination after two weeks of treatment with cerebrolysin. 
Axon diameter (AD), myelin sheath diameter (MSD) and mean 
myelinated fiber diameter (MMFD) showed absence of any significant 
difference between cerebrolysin-received rats and controls; however, 
means of all these indices were higher in the control group as compared 
with the cerebrolysin-received group. Means of AD, MSD and MMFD 
in vehicle and diabetic groups had significant decrease in comparison 
to the control group. This finding shows the efficacy of cerebrolysin in 
the improvement of degenerated axons of nerve fibers or remyelination 
in STZ-induced diabetic rats.
As we mentioned above, our study showed that cerebrolysin (5 ml/
kg/day, ip) can exert positive effects within two weeks in the treatment 
of diabetic neuropathy in male rats. We also expect to have more 
significant effect of cerebrolysin at a different dose level or duration. 
Therefore complementary studies should be done to reveal the optimum 
dose and duration.
Conclusion
It was observed in the present study that intraperitoneal injection of 
cerebrolysin is effective in the treatment of diabetic neuropathy and can 
improve the function of peripheral nerves. 
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